阅读说明：本技术 用于治疗性功能障碍和增强性反应和快感的组合物和方法 (Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure ) 是由 丹尼斯·詹恩 于 2018-11-07 设计创作，主要内容包括：包括至少一种增强性快感的化合物和至少一种增强性敏感性和快感的其他化合物的药物制剂。所述增强性反应的组分增强血液流向生殖器区域。实例包括扩张血管的化合物,如增加血液中一氧化氮(NO)的量的化合物。所述增强性反应和快感的组分包括一种或多种来自大麻(Cannabis)属的大麻素化合物,其包括提取的化合物、合成形式及其衍生物。实例包括四氢大麻酚(THC),这是大麻的主要精神活性成分,以及大麻二酚(CBD),其较少或没有精神活性,并调节THC活性。THC/CBD的比例可以根据使用者的年龄、性别、身体健康和/或心理状况进行选择。(Pharmaceutical formulations comprising at least one compound that enhances sexual pleasure and at least one other compound that enhances sexual sensitivity and pleasure. The sexual response enhancing component enhances blood flow to the genital area. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of Nitric Oxide (NO) in the blood. The sexual response and pleasure enhancing component comprises one or more cannabinoid compounds from the genus Cannabis (Cannabis), including extracted compounds, synthetic forms, and derivatives thereof. Examples include Tetrahydrocannabinol (THC), which is the major psychoactive ingredient of cannabis, and Cannabidiol (CBD), which has little or no psychoactive activity and modulates THC activity. The THC/CBD ratio may be selected according to the age, sex, physical health and/or psychological condition of the user.)

1. A pharmaceutical composition for treating sexual dysfunction in a human comprising one or more dosage forms configured to deliver:

a cannabinoid component comprising at least one of Tetrahydrocannabinol (THC) in a range of 5mg to 500mg or Cannabidiol (CBD) in a range of 5mg to 500 mg; and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil and vardenafil.

2. The pharmaceutical composition of claim 1, wherein the cannabinoid component further comprises at least one of Cannabinol (CBN), Tetrahydrocannabidivarin (THCV), Cannabigerol (CBG), dronabinol (dronabinol), cannabilone (nabilone), a THC derivative, or a CBD derivative.

3. The pharmaceutical composition according to claim 1 or 2, wherein at least a part of the cannabinoid component is obtained from a plant part of one or more plants selected from Cannabis sativa (Cannabis sativa), Cannabis indica (Cannabis indica) and hybrids thereof.

4. The pharmaceutical composition of any one of claims 1-3, wherein the one or more dosage forms are configured to deliver from 7.5mg to 450mg, or from 10mg to 400mg, or from 15mg to 350mg, or from 20mg to 300, or from 25mg to 250mg of THC, or from 35mg to 200mg of THC.

5. The pharmaceutical composition of any one of claims 1-4, wherein the one or more dosage forms are configured to deliver from 7.5mg to 450mg, or from 10mg to 400mg, or from 15mg to 350mg, or from 20mg to 300, or from 25mg to 250mg of THC, or from 35mg to 200mg of CBD.

6. The pharmaceutical composition of any one of claims 1-5, wherein the one or more dosage forms comprise a tablet or capsule.

7. The pharmaceutical composition of any one of claims 1-5, wherein the one or more dosage forms comprise a suppository.

8. The pharmaceutical composition according to any one of claims 1-7, wherein the sexual response enhancing component is vardenafil.

9. The pharmaceutical composition according to any one of claims 1-7, wherein the sexual response enhancing component is sildenafil.

10. The pharmaceutical composition according to any one of claims 1-7, wherein the sexual response enhancing component is tadalafil.

11. An ingestible dosage form for enhancing the sexual response and sensitivity of a human, comprising:

an ingestible cannabinoid component comprising at least one of Tetrahydrocannabinol (THC) in an amount of 5mg to 500mg or Cannabidiol (CBD) in an amount of 5mg to 500 mg; and

a tablet or capsule containing a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil or vardenafil and/or at least 1g, for example at least 2g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yohimbe (Yahimbe) root, ginseng (e.g. red ginseng korea), ginkgo biloba, epimedium (horn coat weed), goosefoot (goose grass), chloranthus japonicus (Chenopodium ambrosides), Chlorophytum (boriville viridum), desmodium adsurae (Dsmodium grandis), garlic combined with vitamin C, and/or damiana (damiana).

12. The ingestible dosage form of claim 11, wherein the ingestible cannabinoid component is a tablet or capsule.

13. The ingestible dosage form of claim 11, wherein the ingestible cannabinoid component is selected from the group consisting of: oral drops, lozenges, lollipops, food preparations (such as brownies, biscuits or chocolate), chews, gummies, soft candies, hard candies and liquid concentrates.

14. A composition for enhancing sexual response and sensitivity in a human comprising:

a topical cannabinoid dosage form comprising at least one of Tetrahydrocannabinol (THC) from 5mg to 500mg or Cannabidiol (CBD) from 5mg to 500 mg; and

a tablet or capsule containing a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil or vardenafil and/or at least 1g, for example at least 2g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yohimbe (Yahimbe) root, ginseng (e.g. red ginseng korea), ginkgo biloba, epimedium (horn coat weed), Chenopodium (goose grass), chloranthus japonicus (Chenopodium ambrosides), Chlorophytum borivilium (chlorimurium), desmodium adscens (Dsmodium grandicum), garlic combined with vitamin C and/or damiana (damiana).

15. The composition of claim 14, wherein the topical cannabinoid dosage form is selected from the group consisting of: massage oil, lotion, gel, cream, lubricant, genital spray, vaginal patch, vaginal suppository, and anal suppository.

16. A composition for enhancing sexual response and sensitivity in a human comprising:

a vaporizable and inhalable cannabinoid dosage form configured to provide at least one of Tetrahydrocannabinol (THC) at a dose of 5mg to 500mg or Cannabidiol (CBD) at a dose of 5mg to 500 mg; and

a tablet, capsule or topical dosage form comprising a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil or vardenafil and/or at least 1g, such as at least 2g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yohimbine root, ginseng (e.g. red ginseng korea), ginkgo biloba, epimedium, goosefoot herb, soil mustard, chlorophytum comosum, desmodium adscendens, garlic combined with vitamin C and/or damiana.

17. The composition of claim 16, wherein the vaporizable and inhalable cannabinoid dosage form is formulated for vaporization and inhalation using a thermal vaporizer.

18. The composition of claim 16, wherein the vaporizable and inhalable cannabinoid dosage form is formulated for vaporization and inhalation using a nebulizer.

19. A method of treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, the method comprising:

by ingestion, inhalation or topical administration of a cannabinoid comprising at least one of Tetrahydrocannabinol (THC) or Cannabidiol (CBD); and

administering by ingestion an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, herbal supplements, and combinations thereof.

20. The method of claim 19, wherein the cannabinoid comprises 5-500mg, or 7.5-450mg, or 10-400mg, or 15-350mg, or 20-300mg, or 25-250mg of THC.

21. The method of claim 19 or 20, wherein the cannabinoid comprises 5-500mg, or 7.5-450mg, or 10-400mg, or 15-350mg, or 20-300mg, or 25-250mg of CBD.

22. The method of at least one of claims 19-21 wherein the cannabinoid comprises THC, CBD, and at least one of Cannabinol (CBN), Tetrahydrocannabivarin (THCV), Cannabigerol (CBG), dronabinol, cannabirone, a THC derivative, or a CBD derivative.

23. The method according to at least one of claims 19-22, wherein the cannabinoid is administered as an injected edible body.

24. The method of at least one of claims 19-22, wherein the cannabinoid is administered as an oral drop or a liquid concentrate.

25. The method of at least one of claims 19-22, wherein the cannabinoid is administered by inhalation of a heat vaporized cannabis extract.

26. The method according to at least one of claims 19-22, wherein the cannabinoid is administered as a capsule or tablet.

27. The method of at least one of claims 19-22, wherein the cannabinoid is administered topically as an oil, lotion, gel, cream, lubricant, genital spray, vaginal patch, vaginal suppository, or anal suppository.

28. The method of at least one of claims 19-27, wherein the sexual response component is administered as a capsule or tablet.

29. The method according to at least one of claims 19 to 28, wherein the reactive component is selected from the group consisting of sildenafil, tadalafil and vardenafil.

30. The method of at least one of claims 19-28, wherein the sexual response component is an herbal supplement selected from the group consisting of: l-arginine, L-citrulline, yohimbine root, ginseng (e.g., Korean red ginseng), ginkgo biloba, epimedium, goosefoot herb, yellow mustard, chlorophytum comosum, desmodium adsurascens, garlic combined with vitamin C, damiana, and combinations thereof.

31. A method of treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, the method comprising:

administering cannabinoids by tablet or capsule, the cannabis extract comprising at least one of Tetrahydrocannabinol (THC) or Cannabidiol (CBD); and

administering an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, L-arginine, herbal supplements, and combinations thereof, via a tablet or capsule.

32. The method of claim 31, wherein the reactive component is selected from the group consisting of sildenafil, tadalafil and vardenafil.

33. A method of treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, the method comprising:

administering a cannabinoid by ingesting a tablet, a capsule, an injected edible body, or a liquid concentrate, the cannabis extract comprising at least one of Tetrahydrocannabinol (THC) or Cannabidiol (CBD); and

administering by ingestion an effective amount of a drug selected from the group consisting of sildenafil, tadalafil and vardenafil.

34. The method of claim 33, wherein the drug comprises sildenafil.

35. The method of claim 33, wherein the drug comprises tadalafil.

36. The method of claim 33, wherein the drug comprises vardenafil.

Technical Field

The present invention is in the field of pharmaceutical formulations, particularly for sexual enhancement in men, women, disabled and elderly.

Background

There are a number of health issues that affect the ability or desire to establish intimacy relationships that form a health component of adult relationships. These include sexual dysfunction and loss of sensitivity and pleasure in both men and women. Failure to track and/or lack of willingness to progress relationships may adversely affect the relationships and may lead to divorce, split hands or long-term boredom. Can result in loss of self-esteem and even mental illness.

Men are more likely than women to have a threshold desire for sexual life (threshold desire), which is both a physiological and psychological need, and therefore more prone to sexual activity with their partner. However, when a male is extremely nervous, anxious or lack of sense of safety, his executive ability may also be physically inhibited (temporary erectile dysfunction). Elderly or diseased men may suffer from chronic erectile dysfunction ("ED"), which may be completely incapacitated with respect to their capacity to perform. Especially as men age and/or if suffering from chronic disease, they may experience a lack of threshold desire, loss of sensitivity, loss of pleasure (collectively referred to as "arousal disorder"), and/or difficulty in reaching orgasm ("orgasmic disorder"). Premature ejaculation, in contrast, severely shortens the duration and reduces the satisfaction of both.

In women, sexual dysfunction is more complex and difficult to define, but may involve a lack of threshold desire, loss of sensitivity, loss of pleasure (collectively "sexual arousal disorder"), and/or failure to reach orgasm ("orgasmic disorder"). Affective and psychological dysfunction may be more common in women. There are many studies that indicate that women often lack a sense of safety with respect to the body image and carry their life stress and anxiety into the bedroom. These insecurities and stresses greatly affect emotional factors (mood and psychological state) and inhibit physiological arousals such as reduced blood flow to the clitoris and labia, often rendering orgasm unrealizable.

Women have a more complex mood than men, which may be a threshold urge disorder. Women have a higher sexual sensitivity to a feeling of insecurity, stress and anxiety than men. It is well known that books and reviewers have the following statements: "sexuality is more emotional for women than for men. Also, men often view sex as a way to relieve and reduce stress and strain. In contrast, women generally believe that sex increases stress and anxiety, particularly women who both work out and foster children. Examples of the assumed pressure include: "I did not have emotion. "I feel stressed or tired from work, children, playing with appointments, managing housework, dirty dishes. "" true? We do so now? "and the like. Therefore, sex may become another item on the list that is already stressful. Examples of the assumed pressure include: "I want I to weigh a few pounds. "" my buttocks are unsightly. "" I felt edema and hormone secretion too much. "how do i compare? "can i do me for my partner, show enough interest, be of interest, etc.? "

Albeit with a drug (e.g. with a drug)And) The physiological condition of ED can be corrected and males allowed to behave sexually, but they do not usually recover lost sensitivity, reduced pleasure, or difficult to reach orgasm. Such drugs are generally not effective in women because they do not adequately address the problems involved: lack of threshold desire, loss of sensitivity, loss or inability to feel pleasureOrgasm is reached (i.e. because they do not really help to solve the powerful psychological forces affecting women).

Indeed, the main reason why physiological enhancers for women in the market today do not work is because they do not address emotional factors. Unlike men, who feel semen accumulation and equate it to sexual stress and need to find sexual release, the triggers of female sexual desire are usually not physical but psychological and are closely related to mood and self-image. In fact, their emotional and psychological state is significantly more determinative of physiological responses, arousals, and manifestations than men. While men are well known terminators of sexual activity, women are not as easy (it is reported that 50% of women never achieve orgasm in sexual activity). Typically this is not due to lack of physical stimulation, but rather to emotional disturbances or suppression. Merely enhancing the physiological response of women is not sufficient to solve the problem of inability to achieve orgasm.

Many of the above problems are particularly acute in men and women suffering from physical disorders and/or age-related conditions that lead to sexual dysfunction and/or lack of desire and enjoyment. Again, the expression does not necessarily coincide with the normal pleasure of sexual relations. Drugs that address only the lack of performance, but not the decline in desire, sensitivity, and pleasure, are incomplete solutions.

Despite the existence of herbal supplements that claim to address some or all of the aforementioned problems, there remains a long-felt but unmet need to find compositions that effectively and reliably address the decline in performance while also increasing desire, sensitivity, and pleasure.

Disclosure of Invention

The present invention relates to pharmaceutical formulations and related methods of manufacture and use for enhancing various aspects of sexual activity and treating sexual dysfunction in both men and women. To achieve these effects, the pharmaceutical formulation comprises a combination of: to achieve these results, the pharmaceutical formulation comprises a combination of (1) one or more cannabinoid compounds derived from a plant of the genus Cannabis (Cannabis) included in an amount and/or in an effective proportion that can increase sexual pleasure (e.g., threshold desire, sensitivity, and/or pleasure); and (2) one or more compounds that enhance blood flow to the genital region to enhance sexual response (e.g., performance and/or arousal time). The combination improves the ability of men and women to perform and enjoy intimate activities that treat one or more of arousal disorder, orgasmic disorder and erectile dysfunction in men and women.

According to several embodiments, the pharmaceutical formulation may be delivered in such a way that the enhanced sexual response and the sexual wellness coincide in time or complement each other (i.e., so that both are present at least some of the time). The delivery methods include oral delivery, topical delivery, injection, inhalation, or combinations thereof. Advantageously, for simple and appropriate dosing, the components of the pharmaceutical formulation may be delivered together in a single delivery mode (e.g., in the form of a combined oral or topical formulation). Alternatively, the components of the pharmaceutical formulation may be prepackaged in a kit and delivered separately, whether simultaneously or sequentially.

According to several embodiments, the one or more cannabinoid compounds derived from cannabis plants include at least two cannabinoid compounds included in amounts and/or ratios to address the particular condition being treated. For example, it has been found that formulations having a relatively higher amount or ratio of Tetrahydrocannabinol (THC) as compared to Cannabidiol (CBD) may benefit persons (male or female) who lack threshold desire, sensitivity, pleasure, and/or orgasmic capacity. Alternatively, a person suffering from premature ejaculation (male) or a person prone to stress or anxiety while engaged in sexual activity (male or female) may benefit from a formulation having a relatively low amount of THC/CBD ratio (e.g., THC/CBD less than 0.5: 1). Persons with normal sexual response may benefit from a moderate THC/CBD ratio (e.g., between 0.5:1 and 2:1 THC/CBD).

As mentioned above, women may have a very real sense of insecurity with their own body image and carry stress and anxiety to the bedroom. Similarly, when a male is extremely stressed, anxious, or lacks a sense of safety, his sexual performance may also be inhibited. Insecurity and stress can greatly affect mood and psychological state, inhibit physiological arousal, and often disable male sexual activity and/or disable female orgasm. However, by addressing both emotional factors (mood and psychological state) and blood flow to the genitals, physical arousal occurs more easily and naturally, which shifts consciousness and focus to sexual sensations, sexual sensitivity and sexual stimulation, thereby enhancing sexual pleasure in men and women and promoting orgasm, and sometimes orgasm.

Detailed Description

Disclosed herein are pharmaceutical formulations comprising at least one hedonic effect enhancing compound and at least one other sexual response enhancing compound. Methods of making and using such pharmaceutical formulations are also disclosed.

The term "sexual pleasure" may include various physiological and/or psychological aspects or conditions that affect the degree of pleasure of sexual activity. Examples include, but are not limited to, threshold desire to begin sexual activity, physical sensitivity during sexual activity, psychological pleasure or awareness during sexual activity, ability to reach orgasm, amount of sensation that causes orgasm, quality of orgasm, duration of orgasm, and the like.

The term "sexual response" may include various physiological and/or psychological aspects that affect the ability to perform sexual activity. In men, the most common condition is failure to achieve or maintain an erection. In women, conditions that inhibit sexual response are more diverse and complex, but include, for example, inability to evoke or delay in evoking when a sexual sensitive area is kissed or touched. In many cases, this inability is more psychological than physiological.

The term "sexual arousal disorder" may apply to both males and females, meaning that a person is difficult to arouse or cannot be aroused or remain aroused during sexual activity.

The term "orgasmic disorder" may be applied to both males and females and refers to a person's persistent or recurrent difficulty in reaching orgasm following sufficient sexual arousal and continued stimulation.

The term "hyposexuality" may be applied to both males and females, and refers to a lack of sexual interest and willingness.

According to several embodiments, the one or more compounds that enhance sexual pleasure ("the pleasure enhancing component") comprise one or more cannabinoid compounds from a cannabis plant. Examples of cannabinoid compounds include tetrahydrocannabinol ("THC"), which is a subgenus of several different isomers with different chiral centers, and is the major psychoactive ingredient of cannabis; cannabidiol ("CBD"), which is less or perhaps even not psychoactive, but may modulate some of the effects of THC in the nervous system, cannabinol ("CBN"), tetrahydrocannabidivarin ("THCV") and cannabigerol ("CBG"). Examples of synthetic cannabinoid compounds include dronabinol (Marinol) (a pure isomer of THC, (-) -trans- Δ 9-tetrahydrocannabinol, the major isomer found in cannabis) and cannabirone (a synthetic racemic mixture consisting of the (S, S) and (R, R) isomers of THC). The synthetic forms of THC and CBD may work as well as plant-based THC and CBD, respectively, and are thus all "cannabis extracts" unless expressly excluded.

Without being bound by any particular theory, it is hypothesized that a pharmaceutical formulation with a higher amount of THC has a stronger excitatory effect on the central nervous system, while a pharmaceutical formulation with a lower amount of THC and/or a higher amount of CBD has a stronger sedative effect. The selection of an optimal combination of excitatory and sedative effects is advantageous for the treatment of a particular sexual dysfunction.

In some embodiments, optimal results may be obtained when the pharmaceutical formulation includes at least two cannabinoid compounds included in amounts and/or ratios that address the particular condition being treated. It will be appreciated that cannabis plants typically have tens of cannabinoids, and that the THC/CBD ratio expressed herein may be most effective when a significant number (e.g. most or all) of the secondary cannabinoid compounds found in cannabis plants are included. Indeed, in at least some instances, the THC/CBD ratio may represent the proportion of other cannabinoid compounds found in a particular cannabis species. Thus, the term "consisting essentially of … …" does not exclude any of the secondary cannabinoid compounds (any or all of which may be present) as long as they do not inactivate or significantly alter the action of THC and/or CBD such that it is no longer recognized.

By way of example, it has been found that persons (male or female) suffering from a lack of threshold desire, sensitivity, pleasure, and/or orgasmic capacity (arousal disorder and/or orgasmic disorder) may benefit from a formulation having a relatively higher amount or proportion of Tetrahydrocannabinol (THC) as compared to Cannabidiol (CBD). Such formulations may be referred to gracefully as "encouraging formulations" or "enhancing formulations". In some cases, the booster formulation may include THC without CBD.

In addition, persons with premature ejaculation (males) or persons prone to stress or anxiety while engaged in sexual activity (males or females) may benefit from formulations having a relatively lower amount or proportion of THC (or a higher ratio of CBD to THC) compared to CBD. Such formulations may be referred to gracefully as "sedative formulations" or "stable formulations". In some cases, a sedative formulation may include CBD and not THC.

In other cases, those without a particular condition but who still wish to enhance sexual experience may benefit from a formulation with a balanced amount or proportion of THC compared to CBD. Such preparations may be referred to gracefully as "intermediate preparations" or "equilibrium preparations". Such formulations typically include both THC and CBD.

According to several embodiments, the amount of THC in the booster formulation may range from about 50mg to about 500mg, or from about 75mg to about 400mg, or from about 100mg to about 300mg per dose. To supplement THC, the amount of CBD in the booster formulation may range from about 10mg to about 250mg, or from about 15mg to about 200mg, or from about 25mg to about 150mg per dose. The ratio of THC to CBD in the enhanced formulation may be at least about 2:1THC/CBD, or in the range of about 2:1 to about 25:1THC/CBD, or about 3:1 to about 20:1THC/CBD, or about 4:1 to about 15:1 THC/CBD.

According to several embodiments, the amount of THC in the stable formulation may range from about 10mg to about 250mg, or from about 15mg to about 200mg, or from about 25mg to about 150mg per dose. To supplement THC, the amount of CBD in the stable formulation may range from about 50mg to about 500mg, or from about 75mg to about 400mg, or from about 100mg to about 300mg per dose. In a stable formulation, the ratio of THC to CBD may be less than or equal to about 0.5:1 THC/CBD. In other words, the ratio of CBD to THC may be at least about 2:1CBD/THC, or in the range of about 0.5:1 to about 25:1CBD/THC, or about 3:1 to about 20:1CBD/THC, or about 4:1 to about 15:1 CBD/THC.

According to several embodiments, the amount of THC in the balanced formulation may range from about 25mg to about 400mg, or from about 50mg to about 300mg, or from about 75mg to about 250mg per dose. To supplement THC, the amount of CBD in the balanced formulation may range from 25mg to about 400mg, or from about 50mg to about 300mg, or from about 75mg to about 250mg per dose. In a balanced formulation, the ratio of THC to CBD may range from about 0.1:1 to about 10:1THC/CBD, or from about 0.25:1 to about 5:1THC/CBD, or from about 0.5:1 to about 2: 1.

While pharmaceutical formulations may fall within the meaning of enhanced, stable or balanced formulations, it is to be understood that these are merely of the euphoric or arbitrary variety for the purpose of teaching general principles as to how to prepare formulations for the treatment of one or more specific conditions. However, the formulation may include such amounts and/or ratios of cannabinoid compounds as to achieve a desired balance between agonism and stability. In many cases, the formulations can be formulated to be both excitatory and stable. The relative degree of excitability and stability may be selected according to the particular condition or sex.

In view of this, compositions containing THC alone or in combination with CBD may comprise THC in the range of from about 10mg to about 500mg, or from about 15mg to about 400mg, or from about 25mg to about 300mg, or from about 50mg to about 250mg, or from about 75mg to about 150mg per dose. The amount of THC may be at least 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 50mg, 60mg, 75mg or 100mg (lower limit value), and at most 750mg, 500mg, 450mg, 400mg, 350mg, 300mg, 250mg, 200mg, 175mg, 150mg, 120mg or 100mg (upper limit value), and the range is defined by the lower limit value and the upper limit value.

Similarly, compositions containing CBD, alone or in combination with THC, may include from about 10mg to about 500mg, or from about 15mg to about 400mg, or from about 25mg to about 300mg, or from about 50mg to about 250mg, or from about 75mg to about 150mg per dose of CBD. The amount of CBD may be at least 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 50mg, 60mg, 75mg, or 100mg (lower limit), and at most 750mg, 500mg, 450mg, 400mg, 350mg, 300mg, 250mg, 200mg, 175mg, 150mg, 120mg, or 100mg (upper limit), and the range is defined by the lower limit and the upper limit.

In conclusion, cannabis has different lines, which include different amounts and/or ratios of various cannabinoid compounds. For example, Cannabis sativa (Cannabis sativa) generally has a higher THC/CBD ratio. In contrast, Indian hemp (Cannabis indica) has a lower THC/CBD ratio than Cannabis sativa (although the absolute content of THC in Indian hemp may be higher than in Cannabis sativa). There are also several hybrids or lines of cannabis sativa and cannabis indicum which have moderate amounts and/or proportions of cannabinoid compounds. The amount and/or ratio of cannabinoid compounds will vary depending on the maturity of the plant, the mode of growth of the plant, the amount of artificial or natural light, the climate, the nutrients and the plant parts used. Generally, the content of cannabinoid compounds is highest in shoots and leaves, and lowest in stems and seeds. Furthermore, leaves, stems and seeds have a lower THC/CBD ratio than shoots of the same plant.

According to several embodiments, a single line or variety of cannabis may be used as a source of cannabinoid compounds in a given pharmaceutical formulation. For example, the enhanced formulation may be prepared by extracting cannabinoid compounds from cannabis sativa or a hybrid of cannabis sativa and cannabis indicum, where cannabis sativa has advantages. In contrast, stable formulations can be prepared by extracting cannabinoid compounds from Indian hemp or hybrids of Indian hemp and Indian hemp, which are more advantageous. A balanced formulation can be prepared by extracting cannabinoid compounds from a hybrid of cannabis sativa and cannabis indicum, where THC and CBD are more balanced (i.e., one compound has less advantage over the other compound than the hybrid used to prepare the enhanced or stable formulation).

According to other embodiments, cannabis of multiple cannabis lines or varieties may be used as a source of cannabinoid compounds in a given pharmaceutical formulation. For example, an enhanced formulation may be prepared by extracting cannabinoid compounds from cannabis sativa and cannabis indica, wherein the number of cannabis sativa is significantly higher. Alternatively, the enhanced formulations may be prepared by extracting cannabinoid compounds from cannabis sativa and one or more hybrids of cannabis sativa and cannabis indica, such as those dominated by cannabis sativa. The enhancing formulation may contain THC and/or CBD of plant origin and/or synthetic origin.

Similarly, a stable formulation can be prepared by extracting cannabinoid compounds from both cannabis sativa and cannabis indica, where the amount of cannabis indica is high. Alternatively, the enhanced formulations may be prepared by extracting cannabinoid compounds from cannabis sativa and one or more hybrids of cannabis sativa and cannabis indica, such as those dominated by cannabis indica. Furthermore, the leaves, stems and seeds of cannabis sativa may naturally have a lower THC/CBD than the shoots of the same plant. The enhancing formulation may contain CBD and/or THC of plant origin and/or synthetic origin.

The balanced preparation can be prepared by extracting cannabinoid compounds from both cannabis sativa and cannabis indica, wherein the cannabis sativa and cannabis indica are present in similar amounts. Alternatively, a balanced preparation may be prepared by extracting cannabinoid compounds from a hybrid of cannabis sativa and cannabis indica, such as one or more preponderantly cannabis sativa and one or more preponderantly cannabis indica. The balancing preparation may contain CBD and/or THC of plant origin and/or synthetic origin.

Examples of marihuana dominant lines include Santa Maria, AK-47, Malawi gold, Bazoka, Durban Poison, Maui Waui, Early Bud, Early Pearl, Early Skunk Plant, Great White Shark, Green Spirit, Haze Skunk, Hempstar, Jack Herer, Kali Mist, Ice, Lamsea x Skunk, Leda Uno, Malawold gold, Niagra x Shiva, Night Queen, Northern Lights x Haze, Power Plant, Purple Haze, Purple Skunk, Smokey beer, Silver Haze, Shagman Couman, Swawerland Swat Island.

Examples of advantageous lines of Indian hemp include Afghani #1, Amstel Gold, Bella Caio, Big Burd, Black Domina, Black African, Black Jack, Chitral, cellulosic Cross, cellulosic Stone, Chronic, DoubleGum, Early Girl, Early Skunk, Eclipse, Euforia, Green Spirit, G-13, Granddaddy Purple, Hawaiian Skunk, Hindu Kush, Holland's Hope, Hypno, HashPlant, Jack, K2, Lemon Stinkky, Bungo, Master Kush, Mazar, Mighty Might, Niagra, Northern Lights, Romu Indlan, Pilica, Purpal, Southern Purple, Southern street, Southern shipment, Starcoarse, and Starflirt.

Examples of more balanced Indian hemp hybrids include Blueberry Kush, Rainbow Kashmiri, Blue Velvet, Blueberry, BubbleBerry, Bubblegum, Buddha Plant, Cali Orange Plant, Durban Poison x light Might, Flo, First Mature, Fourway #1, front strips, Full Moon, Jamaican Pear, Juuicy front, GrapeFruit Haze, Himalayan Gold, Island Lady, KC-33, Keraga x Skunk, Kushage, Northern Berry, NYC Diesel, Pule #1, Purple Kush, Rombey, Shaunk Renski Skii, Whunk Skiir, Swunk shock, fire and Wirtweed.

The cannabinoid compounds can be extracted from one or more cannabis plants using known methods including organic solvent extraction, water extraction using hot or boiling water, mixed solvents using both organic and water, thermal vaporization, fractional distillation, and the like. Depending on the extraction method, the type and/or ratio of cannabinoid compounds may be varied or selected as desired. In general, extraction can better approximate the actual proportion of cannabinoid compounds present in a particular cannabis plant than combustion (i.e. smoking). Burning can severely damage certain cannabinoid compounds and can alter the THC/CBD ratio.

According to several embodiments, the at least one compound that enhances a sexual response ("response-enhancing component") includes one or more compounds that enhance blood flow to the genital area. . Examples of the response-enhancing component include compounds that dilate blood vessels, such as compounds that increase the amount of Nitric Oxide (NO) in blood. These include known drugs and herbal supplements which have been shown to enhance sexual response and improve performance. The response-enhancing component may address physical problems in men's ED and/or women that may inhibit or delay performance, whether from a physical or psychological perspective.

Specific examples of the reaction-enhancing component include sildenafilTadalafilAnd vardenafilThey are drugs and their precursors and metabolites. Compositions within the scope of the present invention may include a pharmaceutically acceptable dose of one or more of the foregoing. The pharmaceutically acceptable dose may depend on the sex, body weight and/or age of the recipient and is within the known guidelines for these well known compounds.

Herbal supplements may also increase the level of NO in the blood to enhance sexual response and improve performance. They include at least 500mg, 1g, 1.5g, 2g, 2.5g, 3g, 4g, 5g, or 6g and up to 20g, 15g, 12g, 10g, 9g, or 8g, or any range between the lower and upper values of the following: l-arginine, L-citrulline, yohimbe (Yahimbe) root, ginseng (e.g., Korean red ginseng), ginkgo biloba, epimedium (horny coat weed), goosefoot (goose foot), chloranthus japonicus (Chenopodium ambrosides), Chlorophytum borivilium, desmodium grandiflorum (Dsmodium grandiflorum), garlic combined with vitamin C, and/or damiana (damiana). Compositions within the scope of the present invention may include one or more of the foregoing in a pharmaceutically acceptable amount (or an amount effective to increase blood NO levels) to enhance the sexual response and improve performance. The pharmaceutically acceptable (or effective) dose may depend on the sex, body weight and/or age of the recipient and is within the known guidelines for such compounds and compositions.

Other herbal supplements are sold under a variety of trade names, including Zytenz, Vydexafil, Oxysurge, Testosyn, KOR Test Booster, Virility Ex, Natural Gain Plus, Extenze, Alpha T1, Happy Endings, Libido Boost Plus, Virect, Male Extra, Climadex, Vendefxa Ultra, Testorev, Magnum Pump XR, VigRX Plus, Ageless apple, Nugenix, Van der,Libidus, Maxidus, Xzen XPress, Xzen Gold, Xzen Platinum, Xzen 1200, Vydexafil, AI Sports Performance, VialKoR, Athletic Edge APE, Axcite Magnum, VirMax, Virilis Pro, Virility-X, XZone, Reload, Mojo Risen, Zoom-Zoom, Love Rider, Ninja Mojo, Mojo Nilights, EreXite, VMaxx Rx, Firminite, compositions within the scope of the invention may include one or more of the foregoing in pharmaceutically acceptable doses (or in amounts effective to increase blood NO levels) to enhance the response and improve performance. The pharmaceutically acceptable (or effective) dose may depend on the sex, body weight and/or age of the recipient and is within the known guidelines for such compounds and compositions.

The amount of the foregoing compound or composition may vary depending on the potency and mode of action. Typically, such compounds or compositions enable a male to achieve and maintain an erection by increasing blood flow to the genital area, for example by causing the body to produce nitric oxide. For reasons that may not be widely understood, it is surprising and unexpected that they are also helpful to women when combined with one or more of the cannabinoid compounds disclosed herein, as they generally have no effect on women when used alone.

Although the ability to perform sexual activity may itself increase sexual pleasure, the response-enhancing component may not itself enhance sexual pleasure (e.g., in a fully healthy male who does not suffer from erectile dysfunction, the use of a response-enhancing drug may not significantly affect sexual pleasure, including orgasm). They may simply provide the fun and novelty of a more permanent and/or faster threshold erection. Similarly, although cannabinoids can cause humans to become "excited" and thus more relaxed and uninhibited, they are also known to reduce sexual response and performance, especially in men. In some cases, they may prevent erection from being achieved or maintained. In other cases, they may unnecessarily prolong or stop the orgasm. Unexpectedly, however, it has now been found that combining one or more reaction-enhancing components with one or more hedonic-enhancing components can optimize the beneficial effects of both while counteracting or eliminating the negative effects. This greatly enhances the overall sexual experience.

More unexpectedly, combining one or more response-enhancing components with one or more hedonic components can provide an elusive aphrodisiac (or "Spanish fly") that has been the subject of mythism and narrative but has not actually been achieved. Unlike men, sexual activity in men is primarily (and logically) physical, and secondarily psychological, women can technically participate in sexual activity, whether or not they are conscious or evoked. As a result, female sexual pleasure is more complex, being both physiological and psychological, or more so. For this reason, sexual activity is usually initiated by males, not females, in both humans and animals. The pharmaceutical formulations disclosed herein can alter this balance and give women more initial threshold desire and actual sexual pleasure, which is beneficial to both women and their sexual partners. Without being bound by any particular theory, it is hypothesized that increasing blood flow to the female genital area, while not proving itself to increase sexual pleasure or response, increases the effect of the cannabinoid compounds both physiologically and psychologically, and thus, when used together, act synergistically to provide increased pleasure and response, as compared to when used alone.

The pharmaceutical formulation may have a variety of different delivery modes, which may be gender specific or customized to the particular needs or desires of the patient. According to one embodiment, the pharmaceutical formulation may be designed topically (external or internal, including body cavities, but not including oral and nasal cavities), such as massage oils, lotions, gels, creams, lubricants, genital sprays, vaginal patches, pessaries, or anal suppositories. Alternatively or additionally, they may be formulated for ingestion, such as capsules, tablets, oral drops, lozenges, lollipops and food preparations, i.e., "edible" (also known as ingestible, as opposed to sublingual or buccal absorption), such as brownies, cookies, chocolates, chews, gummies, hard candies, liquid concentrates (shots), and the like. Alternatively, they may be formulated for inhalation into the lung (e.g., via a thermal vaporizer ("vape") or nebulizer).

Capsules include any delivery form comprising a shell enclosing an active. The shell may be any suitable material known in the art, such as gelatin, starch, cellulose ethers, gums, proteins, or polysaccharides. Tablets include the active substance compressed into a solid form, sometimes with a binder or inert ingredient. While many capsules and tablets are configured to be swallowed whole, they may also be divided into fragments and swallowed, in some cases chewed and swallowed, sometimes crushed by the teeth to release swallowed liquids, gels or solids. Some tablets or capsules may be administered as a suppository through the vagina or anus. Or may be administered orally or sublingually.

"solid ingestible" includes dosage forms that can be swallowed without chewing or with only a small amount of chewing (e.g., certain types of capsules and tablets); chewable and swallowable dosage forms, such as food preparations and other edible bodies (e.g., brownie cakes, cookies, desserts, chocolates, chewies, gummies, and some types of capsules and tablets); dosage forms that dissolve in the mouth and are swallowed (e.g., hard candies, lollipops, lozenges, certain types of capsules and tablets). Solid ingestible features are active ingredients intended to be absorbed through the stomach, intestine and/or small intestine, rather than primarily through the mouth or under the tongue.

"liquid ingestible" includes liquids or gels that can be swallowed with little or no chewing. Solid ingestible features are active ingredients intended to be absorbed through the stomach, intestine and/or small intestine, rather than primarily through the mouth or under the tongue. The liquid ingestible may be a concentrate, a beverage, a gel pack, an oral drop, etc.

The "dual delivery" composition may be applied and absorbed in more than one way. Examples include body oils, creams, lotions, liquids, gels and lubricants, which may be placed on or in an area of the body where they are readily absorbed, such as on the skin, particularly in or on the genital, anal or axillary regions of men or women, and optionally licked or ingested by another party during application and sexual play. In some cases, the composition may be placed on or in the genital (or anal) area of one party and transferred to the genital (or anal) area of the other party during sexual play and intercourse. Such compositions may be placed on or in sexual toys, vibrators, dildos, condoms, other contraceptive devices, props, and the like.

In general, extraction of cannabinoids, followed by delivery without combustion, may provide superior results compared to smoking cannabis and ingesting ED drugs. Burning destroys a large number of cannabinoid compounds and changes their proportions, which makes proper administration difficult. Ingestion and intake of ED drugs also do not control the timing of each, as ingestion results in almost instantaneous stimulation, whereas ingestion of ED drugs requires time for physical metabolism. The result may be a premature cannabinoid effect, while a delayed blood flow-increasing effect occurs together with a reduced cannabinoid effect when it is desired to maximize both. Delivery of hedonic and performance enhancing components in a single formulation and/or in the same manner may provide better control over administration and timing.

Where it is desired to inhale the cannabinoid infused substance, such as a liquid, gel, or paste, vaporizing devices known in the art for delivering nicotine can be used. The concentration of cannabinoids in the e-cigarette juice or oil may be adjusted, similar to when nicotine is delivered using an e-cigarette rod, tube or cartridge, so that a predetermined amount of smoke will deliver a predetermined amount of one or more of the desired cannabinoids.

Nebulizers known in the art for use in hospital, point-of-care or home care can be used to deliver a predetermined amount of cannabinoid.

In addition to cannabinoids, other active substances for increasing blood flow may be delivered by any suitable means to provide a predetermined amount of active substance. These include oral ingestion, topical delivery and inhalation, although oral ingestion by capsules or tablets is currently the most common method of delivery.

Examples

For the purposes of the examples below, hedonic sensations and sexual responses were assigned a value of 1 to 10, with 1 being the lowest and 10 being the highest. Three classifications of males were measured: erectile hardness ranging from 1 to 10; sensitivity, ranging from 1 to 10; and intensity of orgasm, ranging from 1 to 10. Three classifications of women were measured: threshold desire, ranging from 1 to 10; sensitivity, ranging from 1 to 10; and intensity of orgasm, ranging from 1 to 10.

Example 1A

The subject was a 41 year old male. The cannabis variety used to provide cannabinoid compounds is the AK-47 hybrid. Cannabinoid compounds in cannabis are delivered orally using food products. Cannabis plant parts (mainly leaves and buds) were ground, roasted in vegetable oil for 3 hours to extract cannabinoid compounds (mainly THC and CBD), and then filtered. Cannabinoid-infused oils are believed to contain approximately the same proportions of THC and CBD (and other cannabinoids in plant parts) in plant parts. The small amount of cannabinoid did not counteract or significantly alter the main effects of THC and CBD.

According to the instructions, the oil that is injected is used to replace the oil that is required in the normal preparation of a brownie cake. The cannabinoid infused oil was mixed in an amount of 1/4 ounces per 18 ounces of fondant brownie cake mix. Brownie cakes containing the extracted cannabinoid compounds were prepared by placing the mixed batter into a small cake pan (6 square inches) and baking in an oven as specified. A small pan of brownie cake was cut into 3 inch cubes.

The subject ingested two brownie cakes and one XZEN pill. Note that the XZEN used in this and other examples herein was later found to be potentially contaminated with a drug such as sildenafil, tadalafil or vardenafil or biologically similar compounds as it was purchased and modified from the market. The subject began to notice the effects of both after approximately 1 hour and began sexual activity with the female partner shortly thereafter. The subject is able to obtain and maintain a firm erection with increased sensitivity and pleasure during sexual activity. The subject can last longer than usual, in which case sexual activity lasts about 30 minutes. Ejaculation is very violent in orgasm. The statistics are (ranging from 1 to 10): erection hardness: 9; sensitivity: 8; high moisture strength: 10.

example 1B

The female partner in example 1A weighed less than the male subject in example 1A, ingested a block of cannabinoid infused brownian cake, and experienced improved sensitivity (8) and pleasure during sexual activity due to a reduction in anxiety and depression and an increase in threshold urge. The woman does not ingest any blood flow enhancers. It is speculated that the female partner would further benefit from the combined ingestion of an edible cannabinoid with a component that increases blood flow to the female genital area to increase threshold urge (e.g., 8, due to clitoral and labial swelling and thickening), and a more intense orgasm (e.g., 8), due to the combined psychological and physiological effects of ingesting a pleasure-enhancing and performance-enhancing component.

Example 1C

The female partner ingests edible cannabinoids as well as components that increase blood flow to the female genital area. The combination increases the threshold urge (e.g., 8, due to clitoral and labial swelling and thickening), as well as the more intense orgasm (e.g., 8), due to the psychological and physiological effects of the combination resulting from the ingestion of the hedonic and performance enhancing components.

Example 2A

The subject was a 70 year old male. The cannabis variety used to provide cannabinoid compounds is AK-47. The cannabinoid compounds were extracted by simmering 1/4 ounces of cannabis in 1 cup of avocado oil to make butter. The subject spreads approximately 1 tablespoon of butter on a toast, then ingests the toast and one tablet of the XZEN pill on an empty stomach. After 45 minutes, the subject felt the effects of blush and cannabinoid compounds.

One hour later, the subject had a firm erection and started sexual activity with a female partner of similar age. The sexual activity lasted for a striking 2 hours and the subject was able to ejaculate 5 times during this time, which is excellent even for a young person, but in the case where the subject was an elderly male 70 years old. The statistics are (ranging from 1 to 10): erection hardness: 10; sensitivity: 9; high moisture strength: 9. this example illustrates the benefit to the elderly of using cannabinoids with a higher proportion of THC: CBD (at least 2: 1). The subjects' opinion is that sexual as if they were returning to a young age ("returning to 21 years of age") and that his overall mood was significantly improved overall (behavior and temperament), another unexpected benefit.

The female partner in example 2A did not ingest any enhancer. However, it is speculated that a female partner would benefit from ingestion of the formulations disclosed herein and experience an increase in threshold desire (8), increased sensitivity and pleasure (8) and a more powerful orgasm (8).

Example 2B

This example is repeated, but wherein the male ingestsInstead of XZEN, the results were similar. By using any other known male enhancing agent, e.g.Substitution of L-arginine, herba Epimedii, etcOr XZEN, with modifications to this embodiment.

Example 3A

The subject was a 41 year old male. The cannabis variety used to provide cannabinoid compounds is Blueberry Kush. The cannabinoid compounds are delivered orally using food products. Cannabis plant parts (mainly leaves and buds) were ground, roasted in vegetable oil for 3 hours to extract cannabinoid compounds, and then filtered. Cannabinoid-infused oils are believed to contain approximately the same proportions of THC and CBD (and other cannabinoids in plant parts) in plant parts. The small amount of cannabinoid did not counteract or significantly alter the main effects of THC and CBD.

According to the description, the injected oil is used to replace the oil required in the normal preparation of a brownie cake. The cannabinoid infused oil was mixed in an amount of 1/4 ounces per 18 ounces of fondant brownie cake mix. Brownie cakes containing the extracted cannabinoid compounds were prepared by placing the mixed batter into a small cake pan (6 square inches) and baking in an oven as specified. A small pan of brownie cake was cut into 3 inch cubes.

The subject ingested two brownie cakes and one XZen pill. The subject began to notice the effects of both after approximately 1 hour and began sexual activity shortly thereafter. The subject is able to maintain a hard erection and has increased sensitivity. The subject was able to persist for longer periods of time and the sexual activity with the female partner lasted approximately 45 minutes. Ejaculation was very intense. Thereafter, the subject was able to achieve another erection after 30 minutes and started again for about 30 minutes of sexual activity and was able to achieve a second orgasm. The statistics are (ranging from 1 to 10): erection hardness: 9; sensitivity: 8; high moisture strength: 9. this example demonstrates the beneficial effect on relatively young, healthy men over longer lasting abilities compared to examples 1 and 2 when using cannabinoids with a more balanced ratio of THC to CBD (closer to 1:1 than example 1, and possibly less than 1: 1).

Example 3B

The female partner in example 3A ingested a block of cannabinoid infused brownian cake and also experienced increased sensitivity and pleasure during sexual activity (8) due to a reduction in anxiety and suppression and an increase in threshold urge. The woman does not ingest any blood flow enhancers. It is speculated that the female partner would further benefit from the combined ingestion of an edible cannabinoid with a component that increases blood flow to the female genital area to increase threshold urge (e.g., 8, due to clitoral and labial swelling and thickening), and a more intense orgasm (8), due to the combined psychological and physiological effects of the ingestion of a pleasantly-enhanced and performance-enhancing component.

Example 4A

The subject was a 70 year old male. The cannabis variety used to provide cannabinoid compounds is Blueberry Kush. The cannabinoid compounds were extracted by simmering 1/4 ounces of cannabis in 1 cup of avocado oil to make butter. The subject spreads approximately 1 tablespoon of butter on a toast, then ingests the toast and one tablet of the XZEN pill on an empty stomach. After 45 minutes, the subject felt the effects of blush and cannabinoid compounds.

One hour later, the subject had a firm erection and started sexual activity with a female partner of similar age. Sexual activity lasted for 2 hours, and the subject was able to ejaculate 3 times during this time. The statistics are (ranging from 1 to 10): erection hardness: 10; sensitivity: 9; high moisture strength: 9. this example shows that while the subjects ingest a balanced ratio of THC to CBD to obtain significant benefit, the results are not as dramatic as example 2, where the subjects ingest a higher ratio of THC to CBD and are able to achieve 5 orgasms, rather than 3.

The female partner did not ingest any enhancers. However, it is postulated that a female partner would benefit from ingestion of the formulations disclosed herein and experience an increase in threshold desire (8), increased sensitivity and pleasure (8) and a more powerful orgasm (8).

Example 5

A 50 year old male ingested a single brownie cake and one tablet of the XZen pill prepared according to example 3. The subject experiences the effect of both components and is able to erect more quickly and for a longer period of time. The subject performs sexual activity with a female partner for about 30 minutes within about 1-2 hours after ingestion. The subject has an erection of about 8 and an increased sensitivity of about 8; and a more intense orgasm of about 8. It is speculated that the male subject may benefit more with a higher THC: CBD formulation and/or ingest more of the edible body.

The female partner did not ingest any enhancers. However, it is postulated that a female partner would benefit from ingestion of the formulations disclosed herein and experience an increase in threshold desire (8), increased sensitivity and pleasure (8) and a more powerful orgasm (8).

Example 6

The subject was a 22 year old male provided with an infused edible body made according to any of the preceding examples. The subjects were strong and ambitious, but prone to premature ejaculation. The subject is administered the edible body in combination with a component (e.g., XZen or a portion thereof) that increases blood flow to the genital area) Taken together. After 20-30 minutes, the subject erects hard and begins sexual activity with the partner. When an edible body with a high THC to CBD ratio is used, the sexual activity is short (about 1-3 minutes) but intense. The statistics are (ranging from 1 to 10): erection hardness: 10; sensitivity: 8; high moisture strength: 8.

alternatively, the subject ingests a cannabinoid infused edible with a higher proportion of CBD: THC and experiences the same quality of erection, sensitivity and orgasm intensity, but for a much longer period of time than usual (e.g., 15-45 minutes), which greatly enhances the subject's confidence in performing sexual activity with others. Due to the age of the subject, he is able to recover rapidly or immediately between ejaculation to achieve multiple orgasm.

This example shows that while significant benefit is obtained by the subject ingesting a high proportion of THC: CBD, the results are objectively much better when the subject ingests a much lower proportion of THC: CBD (or much higher CBD: THC). It is speculated that a more balanced ratio of THC to CBD would provide a moderate benefit between the extremes described herein.

Example 7

The subject was a 21 year old female provided with an edible body prepared according to any of the preceding examples, which was injected. The subject is healthy, but inexperienced and stressed while engaged in sexual activity, which reduces threshold appetites, pleasure, and satisfaction, and makes it difficult or impossible for the subject to reach orgasm. The subject is administered an edible body and a component (e.g., female XZen or a portion) that increases blood flow to the genital area) Taken together. After about 1 hour, the subject feels flush and experiences the effects of the cannabinoid compound and the blood flow enhancer, including increased swelling of the vulva and papilla (although this is largely physiological), combined with the enhanced psychotropic effect of excitement and reduced anxiety provided by the infused edible body to increase the threshold urge (e.g., 9).

When the subject ingests an edible body that contains a high THC to CBD ratio, the subject may be more physically motivated, but may still have difficulty frequently reaching orgasm. It is speculated that a higher CBD to THC ratio will provide a sedative effect that allows for deeper psychological appreciation and enjoyment of sexual activity, resulting in a more reliable and satisfying orgasm. Depending on the woman, a moderate ratio of THC to CBD may be sufficient to calm, but more exciting, promoting faster and/or multiple orgasms.

Example 8

Providing a 25 year-old female subject with a preparation according to any of the preceding embodimentsThe edible product is ready for injection. The subject is administered an edible body and a component (e.g., female XZen or a portion) that increases blood flow to the genital area) Taken together. After about 1 hour, the subject feels flush and experiences cannabinoid effects, including increased swelling of the vulva and papilla (although this is largely physiological), coupled with the enhanced psychotropic effect of excitement and reduced anxiety provided by the infused edible body, to increase threshold urge.

One hour later, the subject began sexual activity with a male partner of age 41. The subject experiences increased sensitivity (9) and pleasure, and is able to reach orgasm faster and more powerfully than usual. Depending on the endurance of her male sexual partner, the female subject is able to achieve multiple orgasm due to the enhanced physiological and psychological awareness and sensitivity provided by the combined use of the hedonic and performance enhancing components. Due to the age (25 years) and sexual confidence of the female subject, it is speculated that the subject would benefit from an edible body with a balanced THC: CBD ratio as the 41 year old subjects of examples 1 and 3.

Example 9

A female subject 68 years of age with normal sexual experience and activity for her age is provided with the edible body prepared according to any of the preceding examples. The subject is administered an edible body and a component (e.g., female XZen or a portion) that increases blood flow to the genital area) Taken together. After about 1 hour, the subject feels flush and experiences the effects of the cannabinoid compound and the blood flow enhancer, including increased swelling of the vulva and papilla (although this is largely physiological), combined with the enhanced psychoactive stimulation and reduced anxiety provided by the injected edible body to increase the threshold urge.

One hour later, the subject began sexual activity with an age-matched male partner. The subject experienced a high threshold desire (7), high sensitivity (9), and was able to orgasm faster and more forcefully than usual (9). Depending on the endurance of her male sexual partner, the female subject is able to achieve multiple orgasm due to the enhanced physiological and psychological awareness and sensitivity provided by the combined use of the hedonic and performance enhancing components. Due to the age of the female subject (68 years), it is speculated that this subject would benefit from an edible body with a higher THC to CBD ratio as the 70 year old subjects of examples 2 and 4.

Example 10

Providing a 45-year-old female subject with an infused edible body made according to any of the preceding embodiments. The subject is administered an edible body and a component (e.g., female XZen or a portion) that increases blood flow to the genital area) Taken together. After about 1 hour, the subject feels flush and experiences the effects of the cannabinoid compound and the blood flow enhancer, including increased swelling of the vulva and papilla (although this is physiological to a large extent), combined with the enhanced psychotropic effect of the excitation and reduced anxiety provided by the injected edible body, to increase the threshold urge (9).

One hour later, the subject began sexual activity with an age-matched male partner. The subject experiences increased sensitivity (9) and pleasure, and is able to reach orgasm faster and more powerfully than usual. Depending on the endurance of her male sexual partner, the female subject is able to achieve multiple orgasm due to the enhanced physiological and psychological awareness and sensitivity provided by the combined use of the hedonic and performance enhancing components. Due to the age of the female subject (45 years), it is speculated that the subject would benefit more from the edible body having a higher THC: CBD ratio and/or ingest a higher number of edible bodies having a balanced THC: CBD ratio as the 50 year old subject of example 5.

Example 11

Providing an infused edible body made according to any of the preceding embodiments to a 70 year old female subject who is experiencing little sexual activity due to loss of appetite and pleasure. The subject is administered an edible body and a component (e.g., female XZen or a portion) that increases blood flow to the genital area) Taken together. After about 1 hour, the subject feels flush and experiences the effects of the cannabinoid compound and the blood flow enhancer, including increased swelling of the vulva and papilla (although this is physiological to a large extent), combined with the enhanced psychotropic effect of the excitation and reduced anxiety provided by the injected edible body, to increase the threshold urge (7 or 8).

One hour later, the subject began sexual activity with an age-matched male partner. The subject experienced increased sensitivity (7 or 8) and pleasure and was able to reach orgasm (6 or 7), which may be the first time for a long time or history. Depending on the endurance of her male sexual partner, the female subject is able to achieve multiple orgasm due to the enhanced physiological and psychological awareness and sensitivity provided by the combined use of the hedonic and performance enhancing components. Due to the age of the female subject (70 years), it is speculated that this subject would benefit from an edible body with a higher THC to CBD ratio as the 70 year old subjects of examples 2 and 4.

Example 12

Any of the foregoing embodiments are modified by providing at least one component (e.g., a hedonic enhancing component) in a formulation that is deliverable by inhalation. Examples include, for example, a vaporizer that heats one or more components of the pharmaceutical formulation with water or "e-liquid" (e.g., glycerin and/or propylene glycol) to provide a vapor that carries the desired components and can be inhaled. The temperature and/or choice of vaporized liquid can affect the concentration and/or ratio of cannabinoids delivered to the user.

Example 13

Any of the foregoing embodiments may be modified by providing at least one component (e.g., a hedonic enhancing component) in a topical formulation that may be applied to any area of the body where rapid absorption of the active component is possible. Examples include the genital and/or anal regions of, for example, men and women.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.